CoChat

The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario

Open access
Franklyn, Alexandra M., Eibl, Joseph K., Gauthier, Graham, Pellegrini, David, Lightfoot, Nancy E., Marsh, David C. · 2017 · Harm Reduction Journal

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Benzodiazepine use is common among patients in opioid agonist therapy; this puts patients at an increased risk of overdose and death. In this study, we examine the impact of baseline and ongoing benzodiazepine use, and whether patients are more likely to terminate treatment with increasing proportion of benzodiazepine positive urine samples. We also study whether benzodiazepine use differs by geographic location. METHODS: We conducted a retrospective cohort study using anonymized electronic medical records from 58 clinics offering opioid agonist therapy in Ontario. One-year treatment retention was the primary outcome of interest and was measured for patients who did and did not have a benzodiazepine positive urine sample in their first month of treatment, and as a function of the proportion of benzodiazepine-positive urine samples throughout treatment. Cox proportional hazard model was used to characterize one-year retention. RESULTS: Our cohort consisted of 3850 patients, with the average retention rate of 43.4%. Baseline benzodiazepine users had a retention rate of 39.9% and non-users had a retention rate of 44%. Patients who were benzodiazepine negative on admission benefited from an increased median days retained of 265 vs. 215 days. Patients with more than 75% of urines positive for benzodiazepines were 175% more likely to drop out of treatment than those patients with little or no benzodiazepine use. CONCLUSIONS: Baseline benzodiazepine use is predictive of decreased retention. Patients who have a higher proportion of benzodiazepine-positive urine samples are more likely to drop out of treatment compared to those who have little or no benzodiazepine detection in their urine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12954-017-0134-5

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Treatment retention by baseline BZD use. A Cox proportional hazard analysis was used to characterize the time to treatment discontinuation between the patient groups. Log-rank comparison of these curves yielded a chi-square value of 2.883 with a non-significant p value of 0.0895. Baseline BZD users were 14.9% more likely to drop out of treatment than baseline non-users [aHR = 1.15(95% CI 1.02–1.29)]
Fig. 1 Treatment retention by baseline BZD use. A Cox proportional hazard analysis was used to characterize the time to treatment discontinuation between the patient groups. Log-rank comparison of these curves yielded a chi-square value of 2.883 with a non-significant p value of 0.0895. Baseline BZD users were 14.9% more likely to drop out of treatment than baseline non-users [aHR = 1.15(95% CI 1.02–1.29)]CC BY · PubMed Central
Fig. 2 Treatment retention by proportion of BZD-positive urine samples. A Cox proportional hazard analysis was used to characterize the time to treatment discontinuation across the four patient groups. Patients with 25–50% of urines BZD-positive were 26.6% more likely to drop out of treatment than patients in the 0–25% reference group [aHR = 1.26 (95% CI 1.02–1.57)]. Patients with 50–75% of urines BZD-positive were 37.4% more likely to drop out of treatment than patients in the 0–25% reference group [aHR = 1.37(95% CI 1.03–1.832)]. Patients with 75–100% of urines BZD positive were 174.4% more likely to drop out of treatment than patients in the 0–25% reference group [aHR = 2.74(95% CI 2.19–3.43)]
Fig. 2 Treatment retention by proportion of BZD-positive urine samples. A Cox proportional hazard analysis was used to characterize the time to treatment discontinuation across the four patient groups. Patients with 25–50% of urines BZD-positive were 26.6% more likely to drop out of treatment than patients in the 0–25% reference group [aHR = 1.26 (95% CI 1.02–1.57)]. Patients with 50–75% of urines BZD-positive were 37.4% more likely to drop out of treatment than patients in the 0–25% reference group [aHR = 1.37(95% CI 1.03–1.832)]. Patients with 75–100% of urines BZD positive were 174.4% more likely to drop out of treatment than patients in the 0–25% reference group [aHR = 2.74(95% CI 2.19–3.43)]CC BY · PubMed Central
Fig. 3 Proportion of patients retained in treatment for one year, by frequency of BZD use, comparing North vs. South. The pattern of decreased retention with increased proportion of BZD-positive urine samples is not seen in the Southern population, as it is in the Northern population. However, Southern patients with a high proportion of BZD-positive urine samples (≥75%) experienced decreased retention rates
Fig. 3 Proportion of patients retained in treatment for one year, by frequency of BZD use, comparing North vs. South. The pattern of decreased retention with increased proportion of BZD-positive urine samples is not seen in the Southern population, as it is in the Northern population. However, Southern patients with a high proportion of BZD-positive urine samples (≥75%) experienced decreased retention ratesCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 1

  1. Adamson S, S.R., Sheridan J, New Zealand Addiction Treatment Research Monograph. Research Proceedings from the Cutting Edge Conference, September 2010, 2012.

Cited by

See all 39

Metadata

Authors
Franklyn, A. M., Eibl, J. K., Gauthier, G., Pellegrini, D., Lightfoot, N. E., & Marsh, D. C.
Affiliations
  • Laurentian University (CA)
  • NOSM University (CA)
Corresponding author
Marsh, David C.
Venue
Harm Reduction Journal
Published
2017-01-26
Volume
14
Issue
1
Pages
15-15
ISSN
1477-7517 (ISSN-L)
OpenAlex
W2582805122
Cited by
39
References
41
Citations by year
2026: 2 · 2025: 6 · 2024: 1 · 2023: 2 · 2022: 7 · 2021: 7 · 2020: 6 · 2019: 2 · 2018: 3 · 2017: 3
FWCI
3.60
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Harm Reduction Journal (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Northern Ontario Academic Medicine Association
  • Canadian Observational Cohort Collaboration
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
Keywords
benzodiazepine use, opioid substitution therapy, treatment retention, treatment discontinuation, urine drug testing, opioid overdose risk, opioid use disorder
MeSH terms
Adult, Benzodiazepines, Female, Humans, Length of Stay, Male, Methadone, Opioid-Related Disorders, Ontario, Patient Dropouts, Retrospective Studies, Rural Population, Cohort Studies, Treatment Outcome, Opiate Substitution Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario. https://app.cochat.ai/papers/10.1186/s12954-017-0134-5
The paper
Franklyn, A. M., Eibl, J. K., Gauthier, G., Pellegrini, D., Lightfoot, N. E., & Marsh, D. C. (2017). The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario. Harm Reduction Journal. https://doi.org/10.1186/s12954-017-0134-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.